Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies

被引:36
作者
Mastropietro, David J. [1 ]
Omidian, Hossein [1 ]
机构
[1] Nova SE Univ, Coll Pharm, Dept Pharmaceut Sci, Ft Lauderdale, FL 33328 USA
关键词
abuse deterrent; misuse; nonmedical use; opioids; prescription drug abuse; tamper resistant; EXTENDED-RELEASE OXYCODONE; TAMPER-RESISTANT; LISDEXAMFETAMINE DIMESYLATE; OPIOIDS; PHARMACOKINETICS; INDIVIDUALS; LIABILITY; SAFETY; TABLET; IMPACT;
D O I
10.1517/14656566.2014.970175
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Increased misuse and abuse of prescription pain medications has driven extensive research and development to produce what are best known as abuse-deterrent formulations (ADFs). The ADFs are intended to prevent, impede or discourage physical and chemical tampering while still being able to provide safe and accurate delivery of an abusable medication for therapeutic benefit. Areas covered: This review primarily focuses on patents and company literature regarding the formulations, manufacturing and physiochemical properties of abuse-deterrent compositions. Also included are journal articles with relevance to the development of these novel technologies. Particular attention is given to oral dosage forms with applications found in prescription drug products, over-the-counter medications and proprietary technologies in development. Overall, the formulations of 14 drug products, 2 meth-resistant cold products and 17 pharmaceutical proprietary technologies are explored in detail. Expert opinion: Despite the introduction of a wide range of formulation and technology interventions with different deterrence potential, the progression of these technologies seems to be moving from inhibiting only one type of abuse to stopping multiple types of tampering methods. Information on inherent strengths and weaknesses of various formulations can be utilized in the development of more robust and resistant ADF in the future.
引用
收藏
页码:305 / 323
页数:19
相关论文
共 100 条
[1]  
Acura Pharmaceuticals Inc, 2011, STUD AP ADF 107 PHAS
[2]  
Acura Pharmaceuticals Inc, AC NIAC TABL 2014
[3]  
Acura Pharmaceuticals Inc, 2014, AVERSION TECHN
[4]   Development and impact of prescription opioid abuse deterrent formulation technologies [J].
Alexander, Louis ;
Mannion, Richard O. ;
Weingarten, Brianne ;
Fanelli, Richard J. ;
Stiles, Gary L. .
DRUG AND ALCOHOL DEPENDENCE, 2014, 138 :1-6
[5]  
Alpharma Pharmaceuticals LLC, 2010, EMBEDA EXT REL CAPS
[6]  
Andersen C, 2013, Formulations and methods for the controlled release of active drug substances, Patent No. [US 8563038, 8563038]
[7]  
[Anonymous], 2011, TUSS
[8]  
[Anonymous], 2013, FDA STAT OR OP ER RE
[9]  
[Anonymous], 2013, EMBEDA
[10]  
[Anonymous], 2013, RADARS SYSTEM 3 QUAR, V8